SAN
DIEGO, Sept. 1, 2022 /PRNewswire/ -- Avidity
Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company
committed to delivering a new class of RNA therapeutics called
Antibody Oligonucleotide Conjugates (AOCs™), today announced that
the Avidity management team will be participating at the following
upcoming conferences:
- 2022 Wells Fargo Healthcare Conference on Wednesday, September 7 at 1:20pm ET
- Chardan 6th Annual Genetic Medicines Conference
on Tuesday, October 4 at 11:30am
ET
Live webcasts of each event, up-to-date event details and an
archived replay of the webcasts following each event, will be
available on the "Events and Presentations" page in the "Investors"
section of Avidity's website at
https://aviditybiosciences.investorroom.com/events-and-presentations.
About Avidity
Avidity Biosciences, Inc.'s mission is to profoundly improve
people's lives by delivering a new class of RNA therapeutics -
Antibody Oligonucleotide Conjugates (AOCs™). Avidity's proprietary
AOCs are designed to combine the specificity of monoclonal
antibodies with the precision of oligonucleotide therapies to
target the root cause of diseases previously untreatable with RNA
therapeutics. Avidity is on track to have three programs in
clinical development by the end of 2022. The company's lead product
candidate, AOC 1001, is designed to treat patients with myotonic
dystrophy type 1 (DM1). AOC 1001 is currently in Phase 1/2
development with the ongoing MARINA™ trial and MARINA-OLE™ in
adults with DM1. The next programs in the company's advancing and
expanding pipeline are AOC 1044, the lead of three programs for the
treatment of DMD, and AOC 1020, designed to treat people living
with FSHD. Avidity anticipates both programs will enter the clinic
by the end of 2022. Avidity is also broadening the reach of AOCs
beyond muscle tissues through both internal discovery efforts and
key partnerships as the company continues to deliver on the RNA
revolution. Avidity is headquartered in
San Diego, CA. For more information about our
science, pipeline and people, please visit
www.aviditybiosciences.com and engage with us
on LinkedIn and Twitter.
Company Contact:
Kath Gallagher
kath.gallagher@aviditybio.com
(858) 401-7900
View original content to download
multimedia:https://www.prnewswire.com/news-releases/avidity-biosciences-to-participate-in-upcoming-investor-conferences-301616170.html
SOURCE Avidity Biosciences, Inc.